Inhibition of neurite outgrowth in differentiating mouse N2a neuroblastoma cells by phenyl saligenin phosphate: Effects on MAP kinase (ERK 1/2) activation, neurofilament heavy chain phosphorylation and neuropathy target esterase activity

Tools

Hargreaves, A.J. ORCID: 0000-0001-9754-5477, Fowler, M.J., Sachana, M., Flaskos, J., Bountouri, M., Coutts, I.C., Glynn, P., Harris, W. and Mclean, W.G., 2006. Inhibition of neurite outgrowth in differentiating mouse N2a neuroblastoma cells by phenyl saligenin phosphate: Effects on MAP kinase (ERK 1/2) activation, neurofilament heavy chain phosphorylation and neuropathy target esterase activity. Biochemical Pharmacology, 71 (8), pp. 1240-1247. ISSN 0006-2952

Preview

Text
195951_48 Hargreaves PostPrint.pdf
Download (290kB) | Preview

Official URL: http://www.elsevier.com/wps/find/journaldescriptio...

Abstract

Sub-lethal concentrations of the organophosphate phenyl saligenin phosphate (PSP) inhibited the outgrowth of axon-like processes in differentiating mouse N2a neuroblastoma cells (IC50 2.5 μM). A transient rise in the phosphorylation state of neurofilament heavy chain (NFH) was detected on Western blots of cell extracts treated with 2.5 μM PSP for 4 h compared to untreated controls, as determined by a relative increase in reactivity with monoclonal antibody Ta51 (anti-phosphorylated NFH) compared to N52 (anti-total NFH). However, cross-reactivity of PSP-treated cell extracts was lower than that of untreated controls after 24 h exposure, as indicated by decreased reactivity with both antibodies. Indirect immunofluorescence analysis with these antibodies revealed the appearance of neurofilament aggregates in the cell bodies of treated cells and reduced axonal staining compared to controls. By contrast, there was no significant change in reactivity with anti-a tubulin antibody B512 at either time point. The activation state of the MAP kinase ERK 1/2 increased significantly after PSP treatment compared to controls, particularly at 4 h, as indicated by increased reactivity with monoclonal antibody E-4 (anti-phosphorylated MAP kinase) but not with polyclonal antibody K-23 (anti-total MAP kinase). The observed early changes were concomitant with almost complete inhibition of the activity of neuropathy target esterase (NTE), one of the proposed early molecular targets in organophosphate-induced delayed neuropathy (OPIDN).

Item Type:

Journal article

Description:

Post-print

Publication Title:

Biochemical Pharmacology

Creators:

Hargreaves, A.J., Fowler, M.J., Sachana, M., Flaskos, J., Bountouri, M., Coutts, I.C., Glynn, P., Harris, W. and Mclean, W.G.

Date:

2006

Volume:

Number: